ライフサイエンスコーパス: fructosamine

1 ng form aldohexoses showed ions identical to fructosamine.

2 Fructosamine 3-kinase (FN3K) mitigates excessive protein

3 the known oncoprotein and hexose deglycase, fructosamine 3-kinase (FN3K), recognizes and facilitates

4 rs, such as protein deglycation, through the fructosamine-3-kinase (FN3K) enzyme.

5 tions in the level of the deglycating enzyme fructosamine-3-kinase (FN3K) might be associated with th

6 fication and characterization of a mammalian fructosamine-3-kinase (FN3K), which phosphorylates fruct

7 We show that NRF2 activity depends on Fructosamine-3-kinase (FN3K)-a kinase that triggers prot

8 catalytic activity of a conserved family of fructosamine-3-kinases (FN3Ks), which are evolutionarily

9 incident diabetes were 4.96 (4.36-5.64) for fructosamine above the 95th percentile and 6.17 (5.45-6.

10 xidative deglycation of low molecular weight fructosamines (Amadori products).

11 ariable-adjusted HRs for CKD for people with fructosamine and glycated albumin above the 95th percent

12 Fructosamine and glycated albumin are markers of short-t

13 Fructosamine and glycated albumin are markers of short-t

14 as by HbA1c (0.726), but HbA1c outperformed fructosamine and glycated albumin for prediction of inci

15 Our aim was to clarify the performance of fructosamine and glycated albumin measurements for ident

16 We found that fructosamine and glycated albumin were associated with v

17 Elevated baseline concentrations of fructosamine and glycated albumin were significantly ass

18 Fructosamine and glycated albumin were strongly associat

19 Fructosamine and glycated albumin were strongly associat

20 We evaluated associations of fructosamine and glycated albumin with risk of coronary

21 We assessed the associations of fructosamine and glycated albumin with risk of incident

22 den knowledge of the genetic architecture of fructosamine and prioritize FCGRT for downstream functio

23 black and white persons in glycated albumin, fructosamine, and 1,5-anhydroglucitol levels parallel di

24 blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostasis Model Assessment-Insulin R

25 A1C, fructosamine, and in vitro determination of the (14)C-3O

26 ght GH, plasma glucose, free insulin, IGF-I, fructosamine, and lipid profiles were assessed during th

27 ds, colorimetric assay using capillary blood fructosamine as a reference molecule was used.

28 riants and the discrepancy between HbA1c and fructosamines as indicated by the glycation gap.

29 Fructosamine assays were performed blinded to vital stat

30 iabetes was reflected by increases in plasma fructosamine, blood urea nitrogen, creatinine, bilirubin

31 Prediction of incident CKD by fructosamine (C statistic 0.717) and glycated albumin (0

32 al glycemic biomarkers, glycated albumin and fructosamine, can shed light on unknown aspects of type

33 umption (P < 0.01, effect of sugar), whereas fructosamine concentrations did not differ between group

34 iles and fasting plasma glycated albumin and fructosamine concentrations were measured 0, 2, 8, and 1

35 After 19 days of rhIGF-I treatment, fructosamine concentrations were unchanged compared with

36 ein, glucose, glycated hemoglobin A(1c), and fructosamine concentrations; insulin sensitivity; and gl

37 Fructosamine declined from 369 to 299 mumol/l by 3 weeks

38 sease-related risk factors (e.g. glucose and fructosamine), dietary data, and within a subpopulation,

39 de association study of glycated albumin and fructosamine from 7,395 White and 2,016 Black participan

40 asting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable f

41 e combination treatment reduced the elevated fructosamine, glycated hemoglobin, and advanced glycatio

42 We further showed that fructosamine has low heritability (h2 = 7.7%), has no si

43 Recently, fructosamine has shown promising results in predicting a

44 We measured glycated albumin and fructosamine in 11 104 participants with and without dia

45 We measured glycated albumin and fructosamine in blood samples from 11 348 adults without

46 Fructosamine is a good predictor of adverse outcomes in

47 Fructosamine is a measure of short-term glycemic control

48 rades Amadori products oxidatively into free fructosamine, is classified as fructosyl aminocaproate:o

49 R] per 1 SD [1.4 kg], 2.4; 95% CI, 1.6-3.7), fructosamine level (OR per 1 SD [1.1 mumol/L], 2.0; 95%

50 standard deviation (46 micromol) increase in fructosamine level was associated with a 1.3-fold (95% c

51 Fructosamine level, or another indicator of glycemia, sh

52 Of those, 54 patients (4.5%) had elevated fructosamine levels (> 293 umol/L) and these patients we

53 Elevated fructosamine levels (>285 micromol/liter) were associate

54 Based on previous studies on the subject, fructosamine levels above 293 umol/L were used to define

55 ely to develop PJI compared to patients with fructosamine levels below 293 umol/L (p = 0.002).

56 Serum fructosamine levels can be used to estimate long-term se

57 HA were evaluated for glycemic control using fructosamine levels prior to surgery.

58 cantly higher HbA(1c), glycated albumin, and fructosamine levels than white persons before and after

59 The authors examined whether fructosamine levels were associated with mortality in a

60 Likewise, changes in fasting glucose and fructosamine levels were similar.

61 in the relationship of glycated albumin and fructosamine levels with the mean glucose concentration

62 , plasma concentrations of glucose, insulin, fructosamine, lipase, amylase, and TNF-alpha were increa

63 ) plasma concentrations of glucose, insulin, fructosamine, lipase, amylase, and tumor necrosis factor

64 creening test in detecting IFG/IGT or NODAT, fructosamine may be a more accurate diagnostic test but

65 hereas Amadori products were assessed by the fructosamine method.

66 ith open-chain and cyclic structures, of the fructosamine moiety.

67 ass; levels of fasting glucose, insulin, and fructosamine; older age; nonwhite race; family history o

68 en compared with people with no diabetes and fructosamine or glycated albumin below the 75th percenti

69 xidative deglycation of low molecular weight fructosamines or Amadori products.

70 diabetic control (fasting plasma glucose or fructosamine) or by any change in the plasma levels of k

71 Fructosamine oxidase has a lysine near N5 of its flavin.

72 Fructosamine oxidases (FAOX) catalyze the oxidative degl

73 Fructosamine oxidases (FAOXs) are flavin-containing enzy

74 The use of fructosamine oxidases, (Faox) provided promising results

75 Fructosamine (P time=0.035) and homeostatic model assess

76 ycation by phosphorylating and destabilizing fructosamines, preventing irreversible advanced glycatio

77 The fructosamine substrate is oxidized by the flavin in the

78 Key early intermediates in this process are fructosamines, such as protein-bound fructoselysines.

79 -to-C(o) ratio was not correlated with serum fructosamine, suggesting that it was independent of mean

80 comparison with glycation of serum proteins (fructosamine), the glycation gap.

81 e of this study was to assess the utility of fructosamine to predict adverse outcomes following total

82 howed that fasting blood glucose, C-peptide, fructosamine, triglyceride and free fatty acid contents

83 ed by race with HbA1c, glycated albumin, and fructosamine values.

84 deglycates amino acids under release of free fructosamine was isolated.

85 2-hour oral glucose tolerance test (n = 66), fructosamine was the most accurate diagnostic test with

86 5% confidence interval [95% CI], 0.77-0.93), fructosamine was the most accurate test with adjusted AU

87 Patients with elevated fructosamine were also associated with more readmissions

88 d Lys-368 bind the carboxylic portion of the fructosamine, whereas Glu-280 and Arg-411 bind the fruct

89 ctivity of FAOX enzymes toward protein-bound fructosamines, which would have difficulty accessing the